Back to all Current clinical trials
Back to all Current clinical trials
Do you have an advanced solid tumour?
The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: What is the recommended dosing for BGB-B455? What medical problems do participants have when taking BGB-B455? The study has two parts: Phase 1a: dose escalation and safety expansion Phase 1b: dose expansion
What you need to know
Who can take part?
Inclusion:
- Histologically or cytologically confirmed advanced or metastatic, and unresectable solid tumors who have previously received standard systemic therapy for advanced or metastatic disease or for whom treatment is not available or not tolerated
Exclusion:
- Prior systemic anticancer therapy, including chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin), targeted therapy, and antibody drug conjugates (ADCs) that are standard or investigational agents ≤ 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug(s).
What is involved for me?
- 21 day treatment cycles (site visit required Day 1, Day 8 and Day 15)
- Hospital administration post first dose required for monitoring
- Archival or fresh tissue sample required
- Safety assessments including blood tests.
